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Resolution of acute inflammation is normally
accomplished by removal of dying, apoptotic inflam-
matory cells (1, 2). In the cystic fibrosis (CF) lung,
inflammation is persistent and necrotic cells accu-
mulate in the airway (3), suggesting that normal
apoptotic cell removal mechanisms may be impaired.
Recognition of apoptotic cells promotes the resolu-
tion of inflammation in a number of ways. Phagocy-
tosis of apoptotic cells leads to their efficient removal
before disruption of the plasma membranes and
spillage of potentially harmful intracellular contents.
Removal of apoptotic cells also actively suppresses
ongoing inflammation by the production of anti-
inflammatory signals such as TGF-β (4). These anti-
inflammatory signals inhibit inflammatory mediator
production and subsequently enhance resolution of
the response (4, 5).
Apoptotic cells target themselves for recognition and
uptake into phagocytes by expressing surface ligands,
in particular phosphatidylserine (PS) (6, 7). A variety of
receptors are involved in the removal process, especial-
ly a recently cloned specific receptor for PS (8). Other
recognition molecules include CD36 (9), other scav-
enger receptors (10), CD14 (11), a variety of integrins
(12, 13), as well as soluble bridging molecules such as
thrombospondin (9), the collectins (14, 15), or C1q (15,
16). However, the requirement for PS expression (6, 7)
and a dominant role for the PS receptor (8) suggest that
this interaction plays a major role in the recognition
and uptake of apoptotic cells. The PS receptor also
appears critical in the anti-inflammatory effects of
apoptotic cell recognition and initiation of the TGF-β
production, both in vitro (4, 5) and in vivo (17).
The clearance of dying apoptotic cells from devel-
oping tissues or sites of inflammation is normally a
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Cystic fibrosis is characterized by an early and sustained influx of inflammatory cells into the air-
ways and by release of proteases. Resolution of inflammation is normally associated with the order-
ly removal of dying apoptotic inflammatory cells through cell recognition receptors, such as the phos-
phatidylserine receptor, CD36, and αv integrins. Accordingly, removal of apoptotic inflammatory
cells may be impaired in persistent inflammatory responses such as that seen in cystic fibrosis air-
ways. Examination of sputa from cystic fibrosis and non–cystic fibrosis bronchiectasis patients
demonstrated an abundance of apoptotic cells, in excess of that seen in patients with chronic bron-
chitis. In vitro, cystic fibrosis and bronchiectasis airway fluid directly inhibited apoptotic cell removal
by alveolar macrophages in a neutrophil elastase-dependent manner, suggesting that elastase may
impair apoptotic cell clearance in vivo. Flow cytometry demonstrated that neutrophil elastase cleaved
the phosphatidylserine receptor, but not CD36 or CD32 (FcγRII). Cleavage of the phosphatidylser-
ine receptor by neutrophil elastase specifically disrupted phagocytosis of apoptotic cells, implying a
potential mechanism for delayed apoptotic cell clearance in vivo. Therefore, defective airway clear-
ance of apoptotic cells in cystic fibrosis and bronchiectasis may be due to elastase-mediated cleavage
of phosphatidylserine receptor on phagocytes and may contribute to ongoing airway inflammation.
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highly efficient process. Examples include the removal
of apoptotic cells from the limb during embryonic
development, shrinkage of the tadpole tail during
metamorphosis, and loss of apoptotic thymocytes
during normal or steroid-induced involution of the
thymus (1). Despite significant ongoing apoptosis,
remarkably few apoptotic cells can be detected in these
tissues at any point in time due to their rapid clear-
ance (1). In the human respiratory tract, cell removal
during resolution of inflammation is just as efficient.
During the acute respiratory distress syndrome neu-
trophils (PMNs) migrate into the lung in large num-
bers reaching 7.4 × 105/ml (18); however, only 1.6% of
these are apoptotic (18). Similarly, in community-
acquired pneumonia PMNs reach 1.1 × 106/ml (19),
yet only 0.3% are apoptotic (20). This suggests that
extrusion of inflammatory cells into the airway
lumen, by itself, is not a sufficient cause for the accu-
mulation of apoptotic cells.
Accordingly, detection of significant numbers of
apoptotic cells in an inflammatory site, such as the air-
ways of patients with CF and non-CF bronchiectasis,
may suggest dysregulated clearance. Abnormal removal
of apoptotic inflammatory cells in CF could, in turn,
facilitate the persistence or enhancement of airway
inflammation by (a) allowing the development of
postapoptotic necrosis with the consequent release of
proinflammatory materials and by (b) altering mecha-
nisms that would normally actively suppress proin-
flammatory mediator production.
In CF airways, inflammation begins during the
neonatal period, extends through adulthood, and is as-
sociated with chronic bacterial infection, increased IL-8,
TNF-α, PMN influx, and release of PMN proteases
(21–23). Evidence of airway inflammation has been
demonstrated in infants as young as 4 weeks, and a sig-
nificant proportion of infants under 1 year of age have
airway inflammation in the absence of infection (21).
Regardless of the initiating stimulus, the result is mas-
sive influx of inflammatory cells into the airways, where
they die, liberate intracellular proteases that overwhelm
antiprotease defenses (23), and leave proteases unop-
posed to injure airways and impair host defense. This
complex inflammatory milieu in the CF airway may be
considered an extreme manifestation of a pattern of
protease/antiprotease imbalance that appears to be rep-
resentative of a variety of chronic airway inflammatory
diseases, such as bronchiectasis (24), chronic bronchitis
(25, 26), asthma (26), and α1-antitrypsin deficiency (27).
We sought to determine whether apoptotic cells
accumulate excessively in the airways of CF patients
compared with other diseases characterized by chron-
ic airway inflammation and find that airway apoptot-
ic cells are markedly increased in patients with CF and
non-CF bronchiectasis. We further show an impair-
ment of apoptotic cell engulfment induced by fluid
from such airways and demonstrate that this may be
due to the cleavage of the PS receptor from phagocyt-
ic cells by active elastase.
Methods
Materials. Purified human elastase (21 U/mg protein),
human cathepsin G (3 U/mg protein), and the specific
elastase inhibitor, MeOSuc-Ala-Ala-Pro-Val-CMK (NEI),
were obtained from Calbiochem-Novabiochem Corp.
(San Diego, California, USA). The specific cathepsin G
inhibitor (CGI), Z-Gly-Leu-Phe-CMK, was obtained
from Enzyme Systems Products Inc. (Livermore, Cali-
fornia, USA). DMP777, a specific inhibitor of PMN elas-
tase, and its inactive enantiomer, SJ527, were kindly pro-
vided by DuPont Pharmaceuticals Co. (Wilmington,
Delaware, USA). Human proteinase 3 (13.5 U/mg pro-
tein) was obtained from Elastin Products (Owensville,
Missouri, USA). Mouse monoclonal anti-PS receptor
IgM was prepared in this laboratory as described previ-
ously (8). Ab’s obtained from PharMingen (San Diego,
California, USA) included mouse monoclonal anti-
human CD36 IgM, mouse monoclonal anti-human
CD45 IgG, mouse monoclonal anti-human CD32
(FcγRII) IgG, mouse monoclonal anti-keyhole limpet
hemocyanin IgM, and mouse IgG. Ab’s obtained from
Jackson ImmunoResearch Laboratories Inc. (West
Grove, Pennsylvania, USA) included rabbit anti-mouse
IgG, Cy-3 goat IgG anti-mouse IgM, and Cy-3 goat IgG
anti-mouse IgG. Human α1-antitrypsin was obtained
from Sigma Chemical Co. (St. Louis, Missouri, USA).
Human subjects. The study was approved by, and per-
formed in accordance with, the ethical standards of our
institutional review boards on human experimentation.
Written informed consent was obtained from each sub-
ject. Chronic bronchitis patients were current smokers or
had smoked previously and had sputum production for
at least 3 months during 2 successive years. Bronchiecta-
sis was documented in patients using high-resolution
computed tomography, and none were heterozygous, or
homozygous, for 86 known CF mutations (Genzyme
Corp., Framingham, Massachusetts, USA). Bronchiecta-
sis patients included four with a history of Mycobacterium
avium intracellulare, one with allergic bronchopulmonary
aspergillosis, and one with idiopathic bronchiectasis. All
CF patients were homozygous for the ∆F508 CF trans-
membrane regulator mutation, except one who was a
compound heterozygote for ∆F508/R553X.
Sputum was collected from patients in all three groups
during a clinical exacerbation defined by increased
cough and sputum production. Sputum cultures were
taken to identify bacterial or fungal pathogens. All
patients had spirometry within a month of the study.
Assessment of sputum apoptotic cells. First morning spu-
tum was collected on ice and processed immediately
with Sputolysin (Caldon Biotech Inc., Carlsbad, Cali-
fornia, USA), centrifuged onto slides (Cytospin; Shan-
don Inc., Pittsburgh, Pennsylvania, USA), stained with
modified Wright’s Giemsa (Fisher Scientific, Pitts-
burgh, Pennsylvania, USA), and analyzed blindly for
apoptosis using nuclear condensation or a modified
TUNEL assay per the manufacturer’s recommenda-
tions (Promega Corp., Madison, Wisconsin, USA). Spu-
tum alveolar macrophages (AMs) were also examined
662 The Journal of Clinical Investigation | March 2002 | Volume 109 | Number 5
blindly for ingestion of apoptotic cells and quantitat-
ed using a phagocytic index, as described previously (6).
Some samples were assessed for apoptosis using trans-
mission electron microscopy (Philips 400T twin lens;
Philips, Eindhoven, The Netherlands).
Preparation of CF and non-CF bronchiectasis sol. Sol was
made from CF or non-CF bronchiectasis sputum using
a protocol described previously (28). First morning
sputa were collected on ice from hospitalized patients
and fractionated immediately into aqueous sol and gel
fractions by ultracentrifugation (50,000 g for 90 min-
utes). CF sol was pooled from six patients, and non-CF
bronchiectasis sol was pooled from three patients. Elas-
tase and cathepsin G activity were measured using
methods that depended on elastase cleavage of MeO-
Suc-Ala-Ala-Pro-Val-p-nitroanilide (Calbiochem-Nov-
abiochem Corp.) and cathepsin G cleavage of Suc-Ala-
Ala-Pro-Phe-p-nitroanilide (Calbiochem-Novabiochem
Corp.), as described previously (28).
Cell isolation and culture. Human monocyte-derived
macrophages (HMDMs) and PMNs were isolated using
Percoll gradient centrifugation, as described previously
(2). Monocytes were plated in 24-well tissue culture plates
(Becton Dickinson and Co., Franklin Lakes, New Jersey,
USA), and matured to macrophages by culturing in 
X-vivo medium (BioWhittaker Inc., Walkersville, Mary-
land, USA) containing 10% human serum pooled from
five donors, at 37°C in 10% CO2 for 6–8 days. Approxi-
mately 5 × 105 HMDMs were present in each well.
Human AMs were isolated from normal subjects.
Bronchoscopy was performed and subjects were
lavaged with 240 ml 0.9% saline at room temperature.
AMs were resuspended in X-vivo (BioWhittaker Inc.)
medium, cultured in a 96-well plate at 105 cells/well at
37°C in 5% CO2 for 30 minutes, washed to remove
nonadherent cells, and then cultured for 2 hours prior
to experimentation.
Human T lymphocyte Jurkat cells were obtained from
the American Type Culture Collection (Manassas, Vir-
ginia, USA), and human myelomonocyte PLB985 cells
were a kind gift from Christina Leslie (National Jewish
Medical and Research Center, Denver, Colorado, USA).
Both cell lines were cultured in RPMI
(MediaTech Inc., Herndon, Virginia, USA)
with 10% heat-inactivated FBS (Gemini Bio
Products, Calabasas, California, USA) and
supplemented with 2 mM L-glutamine, 100
U/ml penicillin, and 100 µg/ml strepto-
mycin (Sigma Chemical Co.).
Induction of apoptosis. Jurkat cells or
PLB985 cells were exposed to ultraviolet
irradiation at 254 nm for 10 minutes or 5
minutes, respectively, and cultured for 3.5
hours (Jurkat cells) or 2 hours (PLB985
cells). Human PMNs were exposed to ultra-
violet irradiation at 254 nm for 10 minutes
and cultured for 2.5 hours in RPMI with
1% low-endotoxin BSA (Sigma Chemical
Co.). All cells were approximately 70%
apoptotic by nuclear condensation at the time of exper-
imentation, as described previously (2).
Phagocytosis assays. Six- to eight-day-old HMDMs were
cocultured with apoptotic Jurkat cells or PLB985 cells
suspended in 500 µl X-vivo (BioWhittaker Inc.) at 37°C
in 10% CO2 in the absence of human serum for 1 hour
at a ratio of 5:1 (apoptotic cell to HMDM). In some
experiments viable or IgG-opsonized cells (Jurkat cells
only) were used as the target cell. Jurkat cells were
opsonized with mouse monoclonal anti-human CD45
IgG followed by rabbit polyclonal anti-mouse IgG as
described previously (6). HMDMs were then gently
washed with HBSS to remove uningested cells, fixed,
and stained with a modified Wright’s Giemsa stain
(Fisher Scientific). Phagocytosis was determined by
visual inspection of samples and was expressed as a
phagocytic index (6). Each condition was tested in
duplicate and a minimum of 400 HMDMs was count-
ed blindly. HMDMs were greater than 99% viable in the
presence and absence of CF sol, assessed by trypan blue
exclusion. Fresh AMs were cocultured with apoptotic
PMNs in a similar fashion, except experiments were
conducted in 96-well plates.
Reconstitution of plasma membrane outer leaflet with PS.
PLB985 cell membranes were reconstituted with lipids
using liposomes containing a 50:50 molar ratio of PS
to phosphatidylcholine (PC) (both from Avanti Polar
Lipids Inc., Alabaster, Alabama, USA), or 100% PC, as
previously described, and used immediately (7).
FACS analysis. HMDMs or AMs were suspended in
HBSS containing 2% FBS (Gemini Bio Products).
HMDMs or AMs (106) were incubated with 1 µg of pri-
mary Ab on ice for 30 minutes, washed twice, then
incubated with secondary Ab (1:50 dilution) on ice for
30 minutes. Washed macrophages were analyzed on a
FACScan cytometer using PCLysys software (Becton
Dickinson and Co.).
Statistics. The means were analyzed using ANOVA for
multiple comparisons; when ANOVA indicated signifi-
cance, the Tukey-Kramer honestly significant difference
(HSD) test for all pairs was used to compare groups
(Table 1, Figure 1, e and f, and Figure 2, a and c). For all
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Table 1
Patient demographics
Chronic bronchitis Bronchiectasis CF
n 6 6 6
Age (year) 65.5 ± 2.7 63.5 ± 4.7 18.3 ± 1.6A
FEV1 (l) 0.9 ± 0.1 1.3 ± 0.1 1.8 ± 0.2B
FVC (l) 2.2 ± 0.4 2.0 ± 0.1 2.8 ± 0.2
FEV1/FVC (%) 43.8 ± 6.8 63.3 ± 5.0 63.5 ± 6.5
Pseudomonas aeruginosa (mucoid) 0 1 6A
Pseudomonas aeruginosa (nonmucoid) 0 2 1
Staphylococcus aureus 1 0 2
Micobacterium avium intracellulare 0 4C 0
ASignificantly different from chronic bronchitis and bronchiectasis groups (P < 0.05). BSig-
nificantly different from chronic bronchitis group (P < 0.05). CSignificantly different from
chronic bronchitis and CF groups (P < 0.05). FEV1, forced expiratory volume in 1 second; FVC,
forced vital capacity.
other experiments in which an internal control was
present, the Dunnett method was used. All data were
analyzed using JMP (version 3) Statistical Software for
the Macintosh (SAS Institute Inc., Cary, North Caroli-
na, USA) and are presented plus or minus SEM.
Results
Study patients. Patient demographics are summarized
in Table 1. CF patients were younger, had less expira-
tory airflow obstruction, as measured by the forced
expiratory volume in 1 second (FEV1), and were more
likely to be colonized with mucoid Pseudomonas aerug-
inosa. Bronchiectasis patients were more likely to have
been infected with M. avium intracellulare.
Sputum apoptotic cells are increased in patients with CF and
non-CF bronchiectasis. Apoptotic cells were quantitated in
sputum by nuclear condensation (Figure 1a) and by
TUNEL staining. Transmission electron microscopy
demonstrated the presence of early apoptotic, late apop-
totic, and necrotic PMNs in CF sputum (Figure 1, b–d).
Sputum apoptotic cells were present in all patient
groups (Figure 1e). Assessed by nuclear condensation,
apoptotic cells were greater in CF and non-CF
bronchiectasis compared with chronic bronchitis
patients. TUNEL staining confirmed these results; how-
ever, the difference between bronchiectasis and chronic
bronchitis did not reach significance. Sputum samples
were also examined for AM ingestion of apoptotic cells
(Figure 1f). CF AMs contained fewer apoptotic bodies
than those from patients with chronic bronchitis. These
data establish that apoptotic cells are present in the air-
ways of patients with CF, non-CF bronchiectasis, and
chronic bronchitis during clinical exacerbations, but the
relative abundance of apoptotic cells depends upon the
underlying disease. Furthermore, clearance of apoptot-
ic cells by CF AMs appears to be defective.
CF sol impairs macrophage phagocytosis of apoptotic cells in
an elastase-dependent manner. Experiments were conduct-
ed to test whether CF airway fluid impaired the ability
of HMDMs to ingest apoptotic cells (Figure 2a). These
experiments demonstrated that ingestion of apoptotic
Jurkat cells by HMDMs, but not IgG-opsonized or
viable Jurkat cells, was inhibited by 10% CF sol.
Serine proteases, present in the airway secretions of
patients with CF and non-CF bronchiectasis, were
considered as possible contributors to the sol-medi-
ated delay in apoptotic cell clearance. CF sol con-
tained 3 U/ml of PMN elastase and 28 mU/ml of
cathepsin G. Non-CF bronchiectasis sol contained 10
U/ml of PMN elastase and 77 mU/ml of cathepsin G.
Two specific inhibitors of PMN elastase, DMP777 (20
µM) and NEI (100 µM), completely and specifically
inhibited elastase activity in 10% CF and bronchiecta-
sis sol (data not shown). In addition, a specific
inhibitor of cathepsin G, CGI (10 µM), completely
and specifically inhibited cathepsin G activity in both
sol preparations (data not shown).
The specific PMN elastase inhibitor, DMP777, was
used to test whether elastase contributed to the
inhibitory effect of CF sol (Figure 2b). HMDMs cul-
tured with apoptotic Jurkat cells, in the presence of CF
sol, ingested fewer apoptotic cells, but not in the pres-
ence of DMP777. Neither the inactive enantiomer,
SJ527, nor the methylcellulose vehicle prevented the CF
sol-mediated decrease in apoptotic cell ingestion. Simi-
larly, pretreatment of HMDMs with 10% CF sol
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Figure 1
Clearance of apoptotic cells is defective in CF airways. (a) Wright’s Giemsa stain of CF sputum (×100) showing apoptotic cells with con-
densed nuclei (open arrow) and normal PMNs (arrows). (b–d) Transmission electron micrograph of sputum from a CF patient (×6,300;
bars: 1 µm) demonstrating early apoptosis (b), late apoptosis (c), and postapoptotic necrosis (d). Arrows (b and c) indicate condensed
apoptotic nuclei. Arrowheads (d) show loss of membrane integrity during necrosis. (e) Sputa from CF or bronchiectasis patients contain
more apoptotic cells compared with chronic bronchitis. The percentage of apoptotic cells (by nuclear condensation and TUNEL staining)
± SEM is shown for six patients per group. *Apoptosis by nuclear condensation is significantly different from chronic bronchitis (P < 0.05).
**Apoptosis by TUNEL staining is significantly different from chronic bronchitis (P < 0.05). (f) Airway macrophages from CF patients ingest
fewer apoptotic cells. The mean phagocytic index of sputum macrophages ± SEM is shown for six patients per group. *Phagocytic index is
significantly different from chronic bronchitis (P < 0.05).
decreased the phagocytic index during coculture with
apoptotic Jurkat cells (8.5 ± 3.0) compared with control
(22.5 ± 5.5), but not following preincubation of sol with
the natural serine protease inhibitor, α1-antitrypsin, at
100 µg/ml (15.8 ± 0.3) or 1,000 µg/ml (16.5 ± 2.5).
Experiments were performed to establish whether
the effect of CF sol on apoptotic cell phagocytosis was
due to action on the phagocyte, apoptotic cell, or both
(Figure 2c). These data showed that CF sol decreased
ingestion of apoptotic cells following pretreatment of
HMDMs, apoptotic Jurkat cells, or both. DMP777 par-
tially prevented CF sol from impairing phagocytosis
for all three groups tested, but in the case of apoptot-
ic Jurkat cells statistical significance was not reached.
We also tested the possibility that CF HMDMs were
intrinsically defective at ingestion of apoptotic cells.
However, these experiments did not demonstrate any
deficiency in the ability of HMDMs from CF patients
to ingest apoptotic cells compared with normal
HMDMs (data not shown).
These data suggest that CF sol diminishes macrophage
ingestion of apoptotic cells, but not IgG-opsonized cells,
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Figure 2
CF sol inhibits HMDM ingestion of apoptotic but not IgG-opsonized Jurkat cells in an elastase-dependent manner. (a) HMDMs were cocul-
tured with apoptotic, opsonized, or viable Jurkat cells in the presence or absence of 10% CF sol. The mean phagocytic index as percentage of
control ± SEM is shown for three replicates per group. Control mean phagocytic index: 28.6 ± 4.4. *Significantly different from apoptotic Jurkat
cells pretreated with media (P < 0.05). (b) HMDMs were cocultured with apoptotic Jurkat cells in the presence of media (Control), 10% CF sol,
10% CF sol plus DMP777 (100 µM), 10% CF sol plus SJ527 (100 µM), or 10% CF sol plus methyl cellulose (MC). The mean phagocytic index
as percentage of control ± SEM is shown for three to five replicates per group. Control mean phagocytic index: 52.8 ± 10.2. *Significantly dif-
ferent from control (P < 0.05). (c) HMDMs, apoptotic Jurkat cells, or both were pretreated for 30 minutes with media (Control), 10% CF sol,
10% CF sol plus DMP777 (20 µM), or DMP777 (20 µM) alone prior to coculture. Following pretreatment, coculture was done in the presence
of DMP777 (20 µM) to prevent carryover of elastase activity. The mean phagocytic index as percentage of control ± SEM is shown for three
replicates per group. Control mean phagocytic index: 51.4 ± 6.0. *Significantly different from control (P < 0.05). **Significantly different from
10% CF sol-pretreated HMDMs (P < 0.05). ***Significantly different from 10% CF sol-pretreated HMDMs and apoptotic Jurkat cells (P < 0.05).
Figure 3
Elastase, or cathepsin G, inhibits ingestion of apoptotic cells. (a) HMDMs were cocultured with apoptotic Jurkat cells in the presence of media
or increasing concentrations of elastase, cathepsin G, or proteinase 3. The mean phagocytic index as percentage of control ± SEM is shown
for three to six replicates per group. Control mean phagocytic index: 44.1 ± 8.5. *Significantly different from media (P < 0.05). (b) Human
AMs were cocultured with apoptotic human PMNs following pretreatment with media (Control), 1 µM PMN elastase (NE) with or without
a specific elastase inhibitor (NEI, 100 µM), or 1 µM cathepsin G (Cat G) with or without a specific CGI (10 µM). Coculture was done in the
presence of DMP777 (20 µM) to prevent carryover of elastase activity. The mean phagocytic index as percentage of control ± SEM is shown
for three or four replicates per group. Control mean phagocytic index: 8.4 ± 1.9. *Significantly different from control (P < 0.05).
through an elastase-dependent mechanism. Further-
more, CF sol appears to reduce phagocytosis of apop-
totic cells by acting on both the macrophage and the tar-
get apoptotic cell.
PMN elastase and cathepsin G impair macrophage phago-
cytosis of apoptotic but not IgG-opsonized cells. Three serine
proteases with known activity in airway secretions of
CF and non-CF bronchiectasis (elastase, cathepsin G,
and proteinase 3) were evaluated to determine their
effect on HMDM ingestion of apoptotic Jurkat cells
(Figure 3a). Elastase (1 µM, 0.6 U/ml) and cathepsin G
(1 µM, 70 mU/ml) decreased HMDM ingestion of
apoptotic Jurkat cells compared with control. In con-
trast, proteinase 3 had no effect in the concentrations
tested. In addition, 1 µM elastase (13.0 ± 2.5) and 1 µM
cathepsin G (9.8 ± 1.8) had no effect on the ability of
HMDMs to ingest IgG-opsonized Jurkat cells, com-
pared with control (9.8 ± 2.3).
In the airway the AM is the professional phagocyte
that is most likely to be involved with removal of apop-
totic inflammatory cells. Therefore, we sought to test
whether serine proteases interfere with human AM
ingestion of apoptotic PMNs (Figure 3b). AMs were iso-
lated from normal subjects and were cocultured with
apoptotic human PMNs. Elastase (1 µM, 0.6 U/ml) and
cathepsin G (1 µM, 70 mU/ml) inhibited human AM
uptake of apoptotic human PMNs, and this effect was
reversed by the corresponding specific inhibitors. These
results confirmed that human AMs ingest apoptotic
PMNs and that this uptake is inhibited by either PMN
elastase or cathepsin G.
Together, these data establish that elastase and
cathepsin G interfere with phagocytosis of apoptotic
cells by HMDMs and AMs.
Sol from CF and non-CF bronchiectasis inhibits human AM
ingestion of apoptotic PMNs in an elastase-dependent manner.
Experiments were conducted to determine whether sol-
derived serine proteases disrupt the ability of AMs to
remove apoptotic PMNs. These experiments demon-
strated that sol from CF (Figure 4a) and non-CF
bronchiectasis patients (Figure 4b) inhibited human
AM clearance of apoptotic human PMNs and that this
sol effect was prevented by two specific inhibitors of
elastase. In contrast, a specific cathepsin G inhibitor
did not, by itself, prevent the effect of sol on apoptotic
cell removal. These results strongly suggest that elas-
tase, present in the airways of patients with CF or non-
CF bronchiectasis, has the capacity to interfere with
removal of apoptotic PMNs by AMs.
CF sol cleaves the PS receptor in an elastase-dependent man-
ner. Flow cytometry was used to test the effect of CF sol
on macrophage receptors involved with phagocytosis
of apoptotic cells (Figure 5). HMDMs were used in
these experiments; however, all receptors tested were
also present on human AMs (data not shown). CF sol
did not alter staining for CD32 (FcγRII), CD36, or vit-
ronectin receptor (data not shown). In contrast, CF sol
decreased staining for the PS receptor, but not in the
presence of the elastase inhibitor, DMP777. These data
suggest that CF sol elastase may interfere with phago-
cytosis of apoptotic cells through degradation of the PS
receptor. To further test this hypothesis, HMDMs were
incubated with elastase, cathepsin G, or proteinase 3,
and staining for the PS receptor and CD36 was assessed
(Figure 6). Only elastase cleaved the PS receptor at the
concentrations tested.
CF sol elastase impairs PS receptor–mediated phagocytosis of
apoptotic cells. To test the effect of CF sol on PS recep-
tor–mediated phagocytosis, the PLB985 myelomono-
cytic cell line was used. PLB985 cells undergo the typical
nuclear morphologic and biochemical changes charac-
teristic of apoptosis (7). However, undifferentiated
PLB985 cells do not externalize PS from the inner to the
outer membrane leaflet during apoptosis (7). Conse-
quently, they do not interact with PS receptor on the sur-
face of the macrophage to drive ingestion. Reconstitu-
tion of the plasma membrane outer leaflet with PS, but
not PC, increases the ability of macrophages to recognize
and ingest apoptotic PLB985 cells through specific inter-
action with the PS receptor (7).
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Figure 4
CF and non-CF bronchiectasis sol-derived elastase disrupts human
AM ingestion of apoptotic human PMNs. Human AMs were cocul-
tured with apoptotic human PMNs following pretreatment with
media (Control), 10% CF (a), or 10% non-CF bronchiectasis (BR)
(b) sol with or without DMSO, DMP777 (20 µM), NEI (100 µM),
CGI (10 µM), or NEI and CGI. Coculture was done in the presence
of DMP777 (20 µM) to prevent carryover of elastase activity. The
mean phagocytic index as percentage of control ± SEM is shown for
three to four replicates per group. Control mean phagocytic index:
(a) 7.9 ± 1.7; (b) 7.7 ± 1.4. *Groups indicated were significantly dif-
ferent from control (P < 0.05).
The effect of CF sol on phagocytosis of apoptotic cells
through the PS receptor was tested using viable and
apoptotic PLB985 cells (Figure 7). In some PLB985 cells,
membrane PS, or control PC, was reconstituted prior to
coculture. Reconstitution of membrane PS, but not PC,
increased HMDM ingestion of apoptotic PLB985cells,
compared with viable PLB985 cells. In contrast, PS
reconstitution of apoptotic cells did not augment their
engulfment by CF sol-pretreated HMDMs, except in the
presence of DMP777. Therefore, these
results imply that degradation of PS recep-
tor by CF sol elastase directly impairs apop-
totic cell clearance by HMDMs.
Discussion
Three human diseases characterized by
chronic airway inflammation were evalu-
ated to determine whether airway clear-
ance of apoptotic cells might be abnormal.
Our data indicate that apoptotic cells are
present in the sputa from all three groups
studied, but are much more abundant in
patients with CF and non-CF bronchiecta-
sis, compared with those with chronic bron-
chitis. A variety of potential mechanisms
may contribute to accumulation of apop-
totic inflammatory cells in these circum-
stances. However, data presented here sug-
gest that airway elastase inhibits apoptotic
cell clearance through direct action on
macrophage PS receptors. The finding of a
large reservoir of uncleared, dying inflam-
matory cells may have a significant impact
on ongoing airway inflammation.
Increased apoptotic cells in the airways of
patients with CF and non-CF bronchiecta-
sis suggest that the normal kinetics of apoptotic cell
clearance is impaired, since in other PMN-dominated
inflammatory pulmonary diseases efficient clearance
results in very low numbers of apoptotic cells (18, 20).
The airway PMN burden in the acute respiratory dis-
tress syndrome (18) and community-acquired pneu-
monia (19) is similar to that found in clinically stable
CF patients (1.9 × 105/ml) and in CF patients with
clinical exacerbations (1.3 × 106/ml) (29). However, in
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Figure 5
CF sol cleaves PS receptor (PSR) in an elastase-depend-
ent manner. HMDMs were incubated with media (Con-
trol), 10% CF sol, or 10% CF sol plus DMP777 (20 µM)
for 2 hours. Flow cytometry was done to assess surface
staining for CD32 (a and b), CD36 (c and d), and PSR
(e and f). Histograms for each receptor are shown in the
left panels, and the percent of HMDMs that stain for
each receptor ± SEM are shown in the right panels (four
to six replicates per group). *Significantly different from
control (P < 0.05).
Figure 6
Elastase, but not cathepsin G or proteinase 3, cleaves
cell surface PSR. HMDMs were incubated with media
(Control), elastase (1 µM), cathepsin G (1 µM), or
proteinase 3 (1 µM) for 2 hours. Flow cytometry was
done to assess surface staining for PS receptor (a and
b) and CD36 (c and d). Histograms for each receptor
are shown in the left panels, and the percent of
HMDMs that stain for each receptor ± SEM are shown
in the right panels (three replicates per group). *Sig-
nificantly different from control (P < 0.05).
contrast to the acute respiratory distress syndrome
and community-acquired pneumonia, where less than
2% of lavage cells are reported to be apoptotic (18, 20),
we found that more than 25% of inflammatory cells
in CF sputum were apoptotic, 19% were apoptotic in
bronchiectasis, and 3% were apoptotic in chronic
bronchitis. This observation suggests that factors
unique to CF, bronchiectasis, and possibly chronic
bronchitis, may impair the normal apoptotic cell
clearance mechanisms.
Since CF and non-CF bronchiectasis airway lining
fluid significantly blocked uptake of apoptotic cells
into macrophages, inhibitory materials in these airways
were considered prime candidates for the effect. How-
ever, alternate explanations for apoptotic cell accumu-
lation abound and should be considered. (a) We do not
believe that the observed increase in apoptotic inflam-
matory cells is primarily a function of accelerated apop-
tosis. We found that peripheral blood PMNs from CF
patients were not defective at spontaneous or ultravio-
let-induced apoptosis in vitro, measured by morpholo-
gy and PS expression (data not shown). The local air-
way environment (e.g., hyperosmolarity) could increase
the rate of PMN apoptosis (30). However, available evi-
dence strongly suggests that massive apoptosis can be
cleared expediently using normal clearance mecha-
nisms (1). Therefore, accelerated apoptosis by any
means seems unlikely to account, solely, for the
observed accumulation of apoptotic cells. (b) Entrap-
ment of apoptotic cells within airway mucus and/or
altered clearance by an impaired mucociliary escalator
may well contribute to decreased clearance. However,
biopsies of CF airways have demonstrated the presence
of apoptotic cells in the airway walls, suggesting that
these factors are not necessary for apoptotic cells to
accumulate (31, 32). (c) Since most cell types in the
body, including epithelial cells (8, 33), can ingest apop-
totic cells, there may be defects in clearance at the level
of the airway epithelium related to altered CF trans-
membrane regulator function. This might be especial-
ly relevant to early inflammation in CF. However, by
the time inflammatory processes have become persist-
ent, much of the clearance is more likely due to alveo-
lar macrophages. Our studies of monocyte-derived
macrophages from individuals with CF showed no
intrinsic abnormalities in apoptotic cell engulfment
(data not shown). (d) Finally, observed decreases in the
lung collectins, such as surfactant protein A and sur-
factant protein D (34), may also contribute to poor
apoptotic cell clearance, since collectins have been
implicated in apoptotic cell removal (14).
The experiments described herein suggest that the
airway lining fluid contains proteases that are capable
of inhibiting apoptotic cell clearance, in particular elas-
tase and cathepsin G. A variety of proteases are present
in CF airway lining fluid, including elastase (23, 28, 35),
cathepsin G (28, 36), proteinase 3 (37), bacterial pro-
teinases, such as Pseudomonas elastase (38), and metal-
loproteinases (39). While any one of these proteases
potentially may interfere with apoptotic cell phagocy-
tosis, we tested the PMN serine proteases since they are
the most abundant. These studies demonstrated that
CF and non-CF bronchiectasis sol contained elastase
and cathepsin G in high concentrations, similar to
those measured by others (28, 35). However, CF and
non-CF bronchiectasis sol only impaired the ability of
macrophages to ingest apoptotic cells in an elastase-
dependent manner. When tested individually, purified
elastase and cathepsin G both inhibited macrophage
uptake of apoptotic cells, whereas proteinase 3 did not.
This observed difference in the effectiveness of sol-
derived cathepsin G versus purified cathepsin G can
likely be explained by the lower activity of cathepsin G
found in 10% CF sol (2.8 mU/ml) and 10% non-CF
bronchiectasis sol (7.7 mU/ml) compared with the
activity of purified cathepsin G (70 mU/ml) that was
necessary to inhibit apoptotic cell uptake. In contrast,
the concentration of purified elastase (0.6 U/ml) nec-
essary to inhibit apoptotic cell uptake was similar to
that found in 10% CF sol (0.3 U/ml) and 10% non-CF
bronchiectasis sol (1.0 U/ml). While we feel that the pri-
mary effect of sol is on the macrophage, our data also
establishes that CF sol disrupts clearance by acting
directly on the apoptotic cell. Apoptotic cell targets for
this CF sol effect remain obscure; however, possibilities
include protease cleavage of glycoprotein ligands or
direct blockade of externalized PS. This effect of sol
proteases is consistent with our current knowledge of
the protease/antiprotease imbalance that exists in CF
and non-CF bronchiectasis airways, where proteases are
present in excess of their major inhibitors (23, 24).
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Figure 7
CF sol interferes with PS-mediated apoptotic cell ingestion in an elas-
tase-dependent manner. HMDMs were pretreated with media, 10% CF
sol, or 10% CF sol plus DMP777 (20 µM) for 30 minutes prior to
coculture with viable or apoptotic PLB985 cells. PS or PC was insert-
ed into the outer membrane of some apoptotic PLB985 cells by phos-
pholipid transfer. HMDMs were then cocultured for 1 hour with viable
PLB985 cells (Control), apoptotic PLB985 cells, apoptotic PLB985
cells plus PC, or apoptotic PLB985 cells plus PS. Coculture was done
in the presence of DMP777 (20 µM) to prevent carryover of elastase
activity. The mean phagocytic index ± SEM is shown for five replicates
per group. *Significantly different from control (P < 0.05).
Since protease/antiprotease imbalance is also a feature
of chronic bronchitis (25), we would anticipate that
chronic bronchitis sol would also impair clearance of
apoptotic cells, but perhaps to a lesser extent than CF
or non-CF bronchiectasis sol.
Unopposed airway proteases have been shown to
inflict significant damage to host defense by injuring
bronchial epithelial cells, destroying extracellular matrix
components, cleaving immunoglobulin, complement,
and fibronectin (23). Serine proteases may also cleave
cell surface molecules and impair a variety of cell func-
tions including phagocytosis. For example, elastase
inhibits PMN phagocytosis of P. aeruginosa by cleaving
both CR1 and C3bi, creating an “opsonin receptor mis-
match” (40). Elastase also cleaves cell surface antigens
(CD4 and CD8), causing impaired T lymphocyte–medi-
ated cytotoxicity (41), and cathepsin G degrades CD14
on monocytes (42). Our data suggest that elastase in CF
and non-CF bronchiectasis sol interferes with phagocy-
tosis through cleavage of macrophage surface PS recep-
tor. The PS receptor is a recently cloned, small, trans-
membrane phagocyte receptor, present on HMDMs (8,
43) and AMs (data not shown), that drives ingestion of
apoptotic cells through stereospecific recognition of PS
on the outer surface of apoptotic cells. It possesses
potential elastase cleavage sites near the transmembrane
domain that would result in loss of the putative PS-
binding region of the molecule (8). The mechanism by
which cathepsin G interferes with apoptotic cell inges-
tion remains unknown; however, cleavage of CD14, a
receptor known to be involved with apoptotic cell
removal, is one possibility. Alternatively, the PS receptor
may be cleaved by cathepsin G, but cleavage may not be
detected by the techniques used.
Since removal of dying inflammatory cells is an inte-
gral step in the resolution of inflammation, failure of
this process may have proinflammatory consequences
in the airways of patients with CF and non-CF
bronchiectasis. Recognition of apoptotic cells by
phagocytes through the PS receptor is actively anti-
inflammatory, inducing TGF-β, prostaglandin E2 (4),
and under some circumstances, IL-10 (5); these may act
in an autocrine/paracrine manner to suppress produc-
tion of a host of proinflammatory cytokines (TNF-α),
chemokines (IL-8), growth factors, and lipid mediators
(4, 5), similar to inflammatory mediators that are
increased in CF airways (21, 22). Cleavage of the PS
receptor would be expected to block this effect. In con-
trast, macrophage removal of lysed PMNs is much less
effective at inducing TGF-β and inhibiting inflamma-
tory mediators, in part because of its content of elastase
(44). Evidence was presented here that PMNs in CF air-
ways were also undergoing postapoptotic necrosis. This
would be expected to eventually cause release of intra-
cellular contents with potent inflammatory potential,
including the elastase proposed to participate in block-
ade of the apoptotic cell removal.
This concept raises a potential paradox. In the nor-
mal acute inflammatory response, early influx of
PMNs might well be expected to result in some release
of elastase (19, 45) (even though extracellular elastase
secretion is, in fact, not a major event in PMN activa-
tion). Cleavage of the PS receptor would limit produc-
tion of anti-inflammatory cytokines. Why then, do all
acute inflammatory reactions not progress? It would
seem likely that the key limiting factor is the availabil-
ity (influx) of functional antiproteases, which in a “nor-
mal” inflammatory reaction would bring the protease
balance back to normal, allow PS receptor–mediated
generation of anti-inflammatory mediators, appropri-
ate clearance of the apoptotic inflammatory cells, and
resolution of the response.
These results suggest that impaired clearance of
apoptotic cells in diseases characterized by pro-
tease/antiprotease imbalance contributes to the
enhanced inflammatory response and may precipitate
ongoing inflammation and progressive airway dam-
age. Therefore, therapies directed toward relieving
this imbalance may diminish progressive pulmonary
decline by preventing accumulation of apoptotic cells,
subsequent postapoptotic necrosis, and defective res-
olution of inflammation.
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